Adventure Cove s watery world returns Saturday, and Chris Gibson, assistant director of community services, said it seems swimmers are ready to dive in.
Featuring a leisure pool with a zero-depth beach entry, a lazy river, water slides and more, the facility, which has a pirate adventure theme, was built as part of a 2015 bond election.
The aquatic center had a little more than 36,000 patrons visit in the 2019 season, Gibson said.
But COVID-19 soaked 2020 s offering.
With the pandemic seemingly on the wane, the hope is to see crowds return, Gibson said, and the opening Saturday should provide an idea of how many are comfortable getting back out.
Share this article
Share this article
SALT LAKE CITY, May 25, 2021 /PRNewswire/ Recursion Pharmaceuticals, Inc. (Nasdaq : RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning (ML), and engineering, today announced the company has initiated investigational new drug (IND)-enabling studies for REC-163964, a first-in-class, small molecule toxin inhibitor for possible prevention of recurrent Clostridium difficile (C. difficile) infections and potential prophylactic use in high-risk patients.
REC-163964 is the first internally-discovered New Chemical Entity (NCE) development candidate identified by the Recursion Operating System and advanced to IND-enabling studies. This lead represents one of three structurally-differentiated candidates discovered by Recursion s ML-enabled Operating System for the potential treatment of C. difficile.
SR-91: A Lost Mach 5 Spy Plane for the Hypersonic Age nationalinterest.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nationalinterest.org Daily Mail and Mail on Sunday newspapers.